

# A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

NCT06158854

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	AbbVie
Enrollment	76 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Diagnosis of primary systemic immunoglobulin light chain (AL) amyloidosis.
- Eastern Cooperative Oncology Group (ECOG) performance status of  $\leq 2$ .
- Have at least 1 organ historically impacted by AL amyloidosis.
- Considered AL amyloidosis cardiac risk stage 1, 2, or 3a, or considered risk stage 3b with stable cardiac function and markers for 3 months prior to dosing, and have measurable disease of AL amyloidosis as defined by difference between involved and uninvolved free light chains (dFLC)  $\geq 50$  mg/L or meeting high-risk dFLC progression criteria after immediate prior line of therapy.
- Has previously been exposed to a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody.

### Exclusion (12)

- Known history of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.
- Known allergic reaction, significant sensitivity, or intolerance to constituents of the study treatment (and excipients) and/or other products in the same class.
- Participant has the following conditions:
- Other non-AL amyloid disease;
- Previous or current diagnosis of symptomatic multiple myeloma (MM), including the presence of lytic bone disease, plasmacytomas,  $\geq 60\%$  plasma cells in the bone marrow, or hypercalcemia (defined as corrected calcium  $> 11$  mg/dL);
- ... and 7 more (see full listing online)

## Locations (21 total)

---

Sylvester Comprehensive Cancer Center - University of Miami /ID# 255856, Miami, Florida, United States  
Boston Medical Center /ID# 255066, Boston, Massachusetts, United States  
Mayo Clinic - Rochester /ID# 255258, Rochester, Minnesota, United States  
... and 18 more locations

---

<https://clinicaltrials.gov/study/NCT06158854>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.